Victrex plc (VCT), the Lancashire-based high-performance polymer manufacturer, has announced that Dr Ros Rivaz, its Non-Executive Director and Senior Independent Director, has accepted an external board appointment at Porvair plc, effective 12 November 2026. The disclosure was made in accordance with UK Listing Rule 6.4.9 R(2), which requires listed companies to declare external appointments taken on by their directors. The announcement signals an expansion of Dr Rivaz's governance responsibilities across two listed UK companies simultaneously, a development that investors in Victrex may wish to monitor as it relates to board capacity and leadership oversight.

Key Points

  • Victrex plc (VCT) — UK-listed high-performance polymer manufacturer
  • Dr Ros Rivaz, Senior Independent Director at Victrex, appointed Senior Independent Non-Executive Director and Chair of the Remuneration Committee at Porvair plc from 12 November 2026
  • Dr Rivaz will also join Porvair's Audit Committee and Nomination Committee alongside her Victrex duties
  • Investors should watch whether Victrex provides any further commentary on board workload or succession planning at its next scheduled update

Dr Ros Rivaz Appointed Senior Independent Director and Remuneration Committee Chair at Porvair plc

The announcement states that Dr Ros Rivaz has been appointed as Senior Independent Non-Executive Director of Porvair plc, a separate UK-listed company, effective from 12 November 2026. In addition to this senior governance role, Dr Rivaz has been named Chair of Porvair's Remuneration Committee, a position that carries significant responsibility for overseeing executive pay policy and its alignment with shareholder interests. She will further sit on both the Audit Committee and the Nomination Committee at Porvair, meaning she now holds committee responsibilities across multiple governance functions at that company alongside her existing duties at Victrex.

Victrex Disclosure Made Under UK Listing Rule 6.4.9 R(2) Director Declaration Requirements

The company made this disclosure expressly under UK Listing Rule 6.4.9 R(2), which obliges premium and certain other listed issuers to notify the market when a director takes on a material external appointment. This regulatory requirement is designed to ensure transparency around potential conflicts of interest and to allow investors to assess whether a director's time and attention remain sufficiently focused on the listed company in question. Victrex's proactive disclosure reflects its obligations under the Financial Conduct Authority's Listing Rules framework, and the announcement was accompanied by contact details for Kerry Thornton, the Company Secretary.

Dr Rivaz's Dual Role and Its Implications for Victrex Board Governance

Dr Rivaz retains her existing position as both a Non-Executive Director and Senior Independent Director at Victrex, roles that carry considerable governance weight. The Senior Independent Director typically serves as a sounding board for the Chair, leads the annual Chair performance review, and acts as a point of contact for shareholders with concerns. Her concurrent appointment to multiple committees at Porvair raises questions around board time allocation, though the announcement does not indicate that Victrex's board has flagged any concern or plans any change to its current composition as a result of this development.